About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Cardiovascular Therapeutics
›
top-articles
Cardiovascular Therapeutics
2.6
(top 20%)
impact factor
802
(top 20%)
papers
16.1K
(top 10%)
citations
55
(top 10%)
h
-index
2.6
(top 20%)
impact factor
950
all documents
17.1K
doc citations
87
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Relationship between Oxidative Stress and Inflammatory Cytokines in Diabetic Nephropathy
Cardiovascular Therapeutics
2012
505
2
REVIEW: Plasminogen Activator Inhibitor‐1 (PAI‐1): A Key Factor Linking Fibrinolysis and Age‐Related Subclinical and Clinical Conditions
Cardiovascular Therapeutics
2010
340
3
Hypolipidemic, Antioxidant, and Antiinflammatory Activities of Microalgae
Spirulina
Cardiovascular Therapeutics
2010
313
4
Ticagrelor: The First Reversibly Binding Oral P2Y
12
Receptor Antagonist
Cardiovascular Therapeutics
2009
304
5
The Novel Antioxidant Edaravone: From Bench to Bedside
Cardiovascular Therapeutics
2008
192
6
Nutraceuticals and Atherosclerosis: Human Trials
Cardiovascular Therapeutics
2010
185
7
Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review
Cardiovascular Therapeutics
2019
183
8
Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Cardiovascular Therapeutics
2012
138
9
Natural Antioxidants and Hypertension: Promise and Challenges
Cardiovascular Therapeutics
2010
137
10
Xanthine Oxidase Inhibition For The Treatment Of Cardiovascular Disease: A Systematic Review and Meta‐Analysis
Cardiovascular Therapeutics
2012
134
11
The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction
Cardiovascular Therapeutics
2018
132
12
Nutraceuticals in Diabetes and Metabolic Syndrome
Cardiovascular Therapeutics
2010
128
13
REVIEW: Sodium Channel (Dys)Function and Cardiac Arrhythmias
Cardiovascular Therapeutics
2010
128
14
A Novel Hydrogen Sulfide Prodrug,
SG
1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients
Cardiovascular Therapeutics
2015
125
15
Temporal and Spatial Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Following Myocardial Infarction
Cardiovascular Therapeutics
2012
124
16
In-Stent Restenosis
Cardiovascular Therapeutics
2011
120
17
Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factor‐
β
Cardiovascular Therapeutics
2012
112
18
Liver X Receptors (LXR) as Therapeutic Targets in Dyslipidemia
Cardiovascular Therapeutics
2008
111
19
Safety of Herbal Supplements: A Guide for Cardiologists
Cardiovascular Therapeutics
2010
111
20
Dipeptidyl Peptidase‐4 Inhibitors and Cardiovascular Outcomes: Meta‐Analysis of Randomized Clinical Trials with 55,141 Participants
Cardiovascular Therapeutics
2014
111
21
Safety and Feasibility of Levosimendan Administration in Takotsubo Cardiomyopathy: A Case Series
Cardiovascular Therapeutics
2013
104
22
The Cardiovascular Effects of GLP‐1 Receptor Agonists
Cardiovascular Therapeutics
2012
102
23
The Role of Homocysteine‐Lowering B‐Vitamins in the Primary Prevention of Cardiovascular Disease
Cardiovascular Therapeutics
2014
97
24
Serum Levels of Advanced Glycation End Products (AGEs) are Independent Correlates of Insulin Resistance in Nondiabetic Subjects
Cardiovascular Therapeutics
2012
96
25
Myocardial Reverse Remodeling
Cardiovascular Therapeutics
2012
91
26
Assessment of Arterial Stiffness, A Translational Medicine Biomarker System for Evaluation of Vascular Risk
Cardiovascular Therapeutics
2008
89
27
Nutraceuticals and Prevention of Atherosclerosis: Focus on ω‐3 Polyunsaturated Fatty Acids and Mediterranean Diet Polyphenols
Cardiovascular Therapeutics
2010
89
28
Nebivolol: A Highly Selective β
1
‐Adrenergic Receptor Blocker That Causes Vasodilation by Increasing Nitric Oxide
Cardiovascular Therapeutics
2008
88
29
Adiponectin, an Unlocking Adipocytokine
Cardiovascular Therapeutics
2009
88
30
ARIES‐3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension
Cardiovascular Therapeutics
2012
85
31
Erectile Dysfunction in High‐Risk Hypertensive Patients Treated with Beta‐Blockade Agents
Cardiovascular Therapeutics
2010
82
32
Deficiency of a New Protein Associated with Cardiac Syndrome X; Called Adropin
Cardiovascular Therapeutics
2013
81
33
Ginsenoside Re: Pharmacological Effects on Cardiovascular System
Cardiovascular Therapeutics
2012
80
34
RESEARCH: Effects of Long‐Term Disease‐Modifying Antirheumatic Drugs on Endothelial Function in Patients with Early Rheumatoid Arthritis
Cardiovascular Therapeutics
2010
79
35
Cardio‐Selective Beta‐Blocker: Pharmacological Evidence and Their Influence on Exercise Capacity
Cardiovascular Therapeutics
2013
79
36
Drug-induced hERG Block and Long QT Syndrome
Cardiovascular Therapeutics
2011
74
37
Advanced Interatrial Block is Associated with Recurrence of Atrial Fibrillation Post Pharmacological Cardioversion
Cardiovascular Therapeutics
2014
73
38
Antibiotic‐induced Cardiac Arrhythmias
Cardiovascular Therapeutics
2014
71
39
Different Pharmacological Properties of Two Enantiomers in a Unique β-Blocker, Nebivolol
Cardiovascular Therapeutics
2008
70
40
Cilnidipine: A New Generation Ca
2+
Channel Blocker with Inhibitory Action on Sympathetic Neurotransmitter Release
Cardiovascular Therapeutics
2009
70
41
Benefits and Risks of Maintaining Normothermia during Cardiopulmonary Bypass in Adult Cardiac Surgery: A Systematic Review
Cardiovascular Therapeutics
2011
69
42
Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients with Atrial Fibrillation
Cardiovascular Therapeutics
2015
67
43
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (
LCZ
696) in Patients with Heart Failure and Reduced Ejection Fraction
Cardiovascular Therapeutics
2016
67
44
STATIN-D Study: Comparison of the Influences of Rosuvastatin and Fluvastatin Treatment on the Levels of 25 Hydroxyvitamin D
Cardiovascular Therapeutics
2011
66
45
Role and Effective Therapeutic Target of Gut Microbiota in Heart Failure
Cardiovascular Therapeutics
2019
65
46
Soluble Epoxide Hydrolase Inhibitors and Heart Failure
Cardiovascular Therapeutics
2011
63
47
PI3K Inhibitors in Cardiovascular Disease
Cardiovascular Therapeutics
2011
63
48
GLP
‐1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
Cardiovascular Therapeutics
2013
63
49
Opportunity Nox: The Future of NADPH Oxidases as Therapeutic Targets in Cardiovascular Disease
Cardiovascular Therapeutics
2013
63
50
Stimulation of Reactive Oxygen Species and Collagen Synthesis by Angiotensin II in Cardiac Fibroblasts
Cardiovascular Therapeutics
2012
62
site/software ©
exaly
; All materials licenced under
CC by-SA
.